HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in ISI Web of Science Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via ISI Web of Science (1) Citing Articles via Google Scholar Google Scholar Articles by Lovén, J. Articles by Korn, S. H. Search for Related Content PubMed PubMed Citation Articles by Lovén, J. Articles by Korn, S. H.

Anti-inflammatory activity of ß₂-agonists in primary lung epithelial cells is independent of glucocorticoid receptor

Dept of Biological Sciences, AstraZeneca Research and Development Lund, Lund, Sweden.

CORRESPONDENCE: S. H. Korn, Biological Sciences, AstraZeneca, 22187, Lund, Sweden. Fax: 46 46336624. E-mail: Solange.Korn{at}astrazeneca.com

Keywords: Anti-inflammatory, glucocorticoid receptor, granulocyte-macrophage colony-stimulating factor, long-acting ß₂-agonists, small interfering RNA, Western blot

Received: October 4, 2006
Accepted June 21, 2007

In patients with asthma and chronic obstructive pulmonary disease, the addition of long-acting ß₂-agonists (LABA) to glucocorticosteroids (GCS) results in better control than increasing the dose of GCS alone. In smooth muscle cells and fibroblasts, one apparent underlying mechanism involves the ability of LABAs to activate the glucocorticoid receptor (GR).

The present study investigates the effects of formoterol (FORM), salmeterol (SALM) and budesonide (BUD) on GR activation in bronchial epithelial cells via tumour necrosis factor--stimulated granulocyte-macrophage colony-stimulating factor (GM-CSF) release, GR nuclear translocation and GR-regulated reporter gene activity.

Both BUD and FORM inhibited GM-CSF release by 50%. The combination of these two drugs, in clinically relevant concentrations, inhibited GM-CSF release by 85% down to unstimulated levels. A similar inhibition was obtained when combining BUD and SALM. The ability of FORM to inhibit GM-CSF synthesis was not altered by small interfering RNA-mediated depletion of GR and FORM nor SALM-induced GR translocation into the cell nucleus. In addition, FORM did not activate GR-regulated reporter gene activity (SALM was not tested), in contrast to the clear effect of BUD.

It was concluded that in bronchial epithelial cells, inhibition of granulocyte-macrophage colony-stimulating factor synthesis by formoterol and salmeterol does not act via previously demonstrated glucocorticoid receptor-related mechanisms, suggesting an alternative pathway in these cells.